Similarly, in the imiquimod-induced psoriasis model that is IL-23/IL-17/IL-22–dependent (121), tofacitinib significantly reduced epidermal thickening and IL-17+ or IL-22+ lymphocyte infiltration into the dermis (124). This evidence concerns the gene IL17A and psoriasis.